Biostax (BTAX) 10-Q 3 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 03, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-54933
Entity Registrant Name	IMMUNE THERAPEUTICS, INC.
Entity Central Index Key	0001559356
Entity Tax Identification Number	59-3226705
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2431 Aloma Ave.
Entity Address, Address Line Two	Suite 124
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	888
Local Phone Number	613-8802
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		483,714

Condensed Consolidated Balance

Condensed Consolidated Balance Sheet - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 436,888	$ 493,885
Investment in common stock	362,250	2,645,000
Total current assets	799,138	3,138,885
Total Assets	799,138	3,138,885
Current Liabilities:
Accounts payable	2,171,020	2,184,848
Accrued payroll	3,425,796	3,421,176
Notes payable, net of debt discount	3,070,208	3,070,208
Net due to related parties	981,421	891,420
Undocumented investor advances	715,631	715,631
Accrued interest	656,484	564,300
Accrued liabilities	283,384	239,558
Total current liabilities	11,303,944	11,087,141
Total Liabilities	11,303,944	11,087,141
Commitments and Contingencies
Stockholders’ Deficit:
Common stock – par value $0.0001; 750,000,000 and 500,000,000 shares authorized, respectively; 483,714 shares issued and outstanding	49	49
Additional paid in capital	371,473,810	371,473,810
Stock issuances due	10,303	10,303
Accumulated deficit	(381,988,968)	(379,432,418)
Stockholders' Equity Attributable to Parent	(10,867,056)	(7,948,256)
Total Liabilities and Stockholders’ Deficit	$ 799,138	$ 3,138,885

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheet (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	500,000,000
Common stock, shares issued	483,714	483,714
Common stock, shares outstanding	483,714	483,714

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Selling, general and administrative	$ 181,616	$ 138,726
Research and development expense		148,693
Total operating expenses	181,616	287,419
Loss from operations	(181,616)	(287,419)
Other (expense) income:
Decrease in carrying value of common shares	(2,282,750)
Interest expense	(92,184)	(100,404)
Gain on derivative liability revaluation		1,178,230
Total other (expense) income	(2,374,934)	1,077,826
Net (loss) income	$ (2,556,550)	$ 790,407
Basic (loss) income per share attributable to common shareholders	$ (5.29)	$ 1.65
Diluted (loss) income per share to common shareholders	$ (5.29)	$ 0.05
Basic weighted average number of shares outstanding	483,714	478,305
Diluted weighted average number of shares outstanding	483,714	16,594,895

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity/(Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock To Be Issued [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 48	$ 371,341,120	$ 10,303	$ (383,018,452)	$ (11,666,981)
Beginning balance, shares at Dec. 31, 2020	476,504
Issuance of common stock upon conversion of debt	$ 1	56,479			56,480
Issuance of common stock upon conversion of debt, shares	5,402
Extinguishment of derivative liability upon conversion of debt		76,211			76,211
Net income (loss)				790,407	790,407
Ending balance, value at Mar. 31, 2021	$ 49	371,473,810	10,303	(382,228,045)	(10,743,883)
Ending balance, shares at Mar. 31, 2021	481,906
Beginning balance, value at Dec. 31, 2021	$ 49	371,473,810	10,303	(379,432,418)	(7,948,256)
Beginning balance, shares at Dec. 31, 2021	483,714
Net income (loss)				(2,556,550)	(2,556,550)
Ending balance, value at Mar. 31, 2022	$ 49	$ 371,473,810	$ 10,303	$ (382,351,800)	$ (10,867,056)
Ending balance, shares at Mar. 31, 2022	483,714

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (2,556,550)	$ 790,407
Adjustments to reconcile net (loss) income to net cash flows used in operating activities:
Decrease in carrying value of common shares	2,282,750
Change in value of derivative		(1,178,230)
Amortization of debt discount		34,789
Changes in operating assets and liabilities:
Deposits		53
Accounts payable	(13,828)	147,965
Accrued payroll	4,620
Accrued interest	92,184	65,613
Accrued liabilities	43,826	46,500
Due to related parties	90,001	94,590
Net cash from operating activities	(56,997)	1,687
Net increase in cash and cash equivalents	(56,997)	1,687
Cash and cash equivalents at beginning of period	493,885	9,971
Cash and cash equivalents at end of period	436,888	11,658
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Conversion of debt and accrued interest to common stock		$ 56,480

Company Overview

Company Overview	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company Overview	1. Company Overview Immune Therapeutics Inc. (the “Company” or “IMUN”) is a Florida Public Company trading on the OTC-Pink. The Company has been inactive for the last year due to a lack of funding, and with the Company’s current structure, it is impossible to move forward until a restructuring of the Company is completed. Going Concern As of March 31, 2022, the Company had $ 436,888 in cash on hand, negative working capital of $ 10,867,056 and a stockholders’ deficit of $ 10,504,806 . For the first quarter ended March 31, 2022, the Company reported a net loss attributable to common shareholders of $ 2,556,550 . For the three months ended March 31, 2021, the Company reported net income attributable to common shareholders of $ 790,407 . Included in net income for the first quarter of 2021 was a non-cash non-operating gain of $ 1,178,230 resulting from elimination of a derivative liability upon the satisfaction of the underlying debt instrument. Historically the Company has relied on the funding of operations through private equity financings and management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of product candidates as they become available and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Working capital on March 31, 2022 is not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. Management is developing as a strategy to re-capitalize the Company and position it for future growth. Key steps to this process include: ● Improve the condition of the balance sheet via license arrangements and capital infusions ● Identify and acquire late-stage assets for commercialization ● Build out operational infrastructure to generate revenue opportunities to grow shareholder value. There can be no guaranties that the Company will be successful in securing adequate capital to continue operations and in identifying and acquiring assets for future development. If the Company is unable to secure new working capital, other alternatives strategies will be required. Historically, the Company has been able to acquire and develop assets, spin them out and retain both an equity stake and royalties and milestone payments. In so doing, the Company has acted as an incubator for late-stage drug development. Management believes that this strategy can continue to be successful. At this time, the Company is reviewing several opportunities which it may pursue as soon as funding is available. At present no definitive actions have been taken. There can be no guaranties that the Company will be successful in: ● Executing its restructuring plan ● Securing adequate capital to continue operations. ● Identifying and acquiring assets for future development. Company History Immune Therapeutics, Inc. (“the Company”, “Immune”) was initially incorporated in Florida on December 2, 1993, as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998, and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014, changing our name to Immune Therapeutics, Inc.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2021 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value . Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000 Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of the Company’s investment in the common stock of Statera BioPharma, Inc. (“STAB”) has been measured based on the quoted per share price as reported on NASDAQ and reflects an impairment loss as of March 31, 2022. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of March 31, 2022 and 2021, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2022, and 2021, the Company does not have any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company did not grant any stock-based compensation awards during the three months ended March 31, 2022 and 2021. The Company measures and recognizes compensation expense for share-based awards based on estimated fair values equalling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation-Stock Compensation Net (Loss) Income per Share For the three months ended March 31, 2022, basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For the three months ended March 31, 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. The Company’s potential dilutive securities, which include stock warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. For the three-month ended March 31, 2021, basic net income per share was calculated by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted income per share, for the three-month period ended March 31, 2021, was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method and the if-converted method. A reconciliation for the three-month period ended March 31, 2021 of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Diluted Earnings per Share Net Income Weighted Average Per Share Amount Basic EPS Income available to common stockholders $ 790,407 478,305 $ 1.65 Diluted EPS Effect of warrants convertible into common stock - 20,012,083 - Potential shares purchasable using proceeds of warrants - (3,925,915 ) - Effect of convertible debt - 30,422 - Income available to common stockholders $ 790,407 16,594,895 $ 0.05 Recent Accounting Standards The Company has reviewed the accounting pronouncements issued by the Financial Accounting Standards Board during the first quarter 2022. Applicable pronouncements will be adopted by the Company in accordance with the accounting guidance and definition. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Investment in Common Stock

Investment in Common Stock	3 Months Ended
	Mar. 31, 2022
Investment In Common Stock
Investment in Common Stock	Note 3. Investment in Common Stock In 2021, Cytocom, Inc., a former subsidiary of the Company (“Cytocom”), announced the completion of its merger with Cleveland BioLabs, Inc. (“CBLI”) which resulted in the Company’s receipt of 1,150,000 common shares of CBLI, reflecting the Company’s retained minority interest in Cytocom. In accordance with the reporting requirements of FASB ASC Topic 321, “Investments Equity Securities”, the Company re-measured the fair value of the STAB common shares at $ 0.32 per share and recognized a decrease in market value of $ 2,282,500 as of March 31, 2022.

Notes payable

Notes payable	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Notes payable	4. Notes payable Notes Payable on March 31, 2022 and December 31, 2021: Schedule of Notes Payable March 31, 2022 December 31, 2021 $ 70,000 $ 70,000 Promissory notes issued between December 2014 and January 2015. Lender earns interest at 10 36 $ 70,000 $ 70,000 Promissory notes issued between May 2015 and June 2016 and matured between February 2017 and November 2018 2 10 $ 149,500 149,500 Promissory notes were issued in 2016. The notes accrue interest at 2 November 2017 and December 2017 $ 606,500 606,500 Promissory notes were issued in 2017 accrue interest at 2 January 2018 and September 2018 $ 205,000 205,000 Promissory notes were issued in 2017 accrue interest at 2 May 2018 $ 150,000 150,000 Promissory notes were issued in 2017 accrue interest at 2 August 2018 and September 2018 $ 116,800 116,800 Promissory notes were issued in 2017 accrue interest at 2 $ 105,500 105,500 Promissory notes were issued in the 2018 accrue interest at 2 May 2018 and January 2019 $ 47,975 47,975 Promissory notes were issued in 2018 accrue interest at 2 July 2018 and October 2018 1,000 5,000 5 $ 65,000 65,000 Promissory notes were issued in 2018. The notes accrue interest at 2 August 2019 and January 2019 60,000 500,000 0.05 $ 118,000 118,000 Promissory notes were issued in 2018. The notes accrue interest at 2 January 2019 and November 2019 200 39,500 5 40 $ 323,855 323,855 Promissory note was issued to a related party in the first quarter of 2019. The note accrues interest at 2 July 2019 4,600 5 $ 23,000 23,000 Promissory note was issued in the first quarter of 2019. The note accrues interest at 6 February 2020 $ 231,478 231,478 Promissory note was issued in the second quarter of 2019 accrues interest at 2 July 2019 10,000 5 $ 10,000 10,000 Promissory note issued in October 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15 1,875 April 30, 2021 $ 150,000 150,000 Promissory note issued in the third quarter of 2020 accrues interest at 12 August 2021 5,402 February 2021 - 53,000 Promissory notes issued in the first quarter of 2021 in connection with a Note Purchase Agreement with a previous note holder. The new notes reflect all principal, interest and penalties associated with the original instrument. These notes accrue interest at 5 7 348,800 March 2022 $ 697,600 697,600 $ 3,070,208 $ 3,070,208 As of March 31, 2022, the Company had accrued $ 656,484 1,677,275 1,677,275

Capital Structure _ Common Stoc

Capital Structure – Common Stock and Stock Purchase Warrants	3 Months Ended
	Mar. 31, 2022
Capital Structure Common Stock And Stock Purchase Warrants
Capital Structure – Common Stock and Stock Purchase Warrants	5 Capital Structure – Common Stock and Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. Stock Warrants During the three months ended March 31, 2022 and March 31, 2021, no warrants issued or exercised. There were no modifications to the terms of any warrants issued by the Company during these periods. On March 31, 2022, the Company had a total of 20,057,006 warrants rights outstanding. Included in the outstanding warrants are 18,730,000 warrants, held by thirty-one investors with an exercise price of $ 5.00 per share, that include provisions that limit the maximum impact of a reverse split on their warrant shares and the exercise price per share at 10-to-1 . The following is a summary of outstanding common stock warrants for the three-month period ended March 31, 2022. Schedule of Outstanding Common Stock Warrant Expiration Date Number of Shares Exercise Price Remaining Life (years) Second Quarter 2022 1,750 $ 150 .25 Third Quarter 2022 1,650 $ 50 100 .50 Fourth Quarter 2022 9,811 $ 80 290 .75 First Quarter 2023 1,204,000 $ 5 40 1.00 Second Quarter 2023 802,000 $ 5 200 1.25 Third Quarter 2023 7,521,500 $ 5 100 1.50 Fourth Quarter 2023 6,024,300 $ 2 5 1.75 First Quarter 2024 3,660,000 $ 5 2.00 Second Quarter 2024 800,000 $ 5 2.25 Third Quarter 2028 3,000 $ 70 6.50 Second Quarter 2032 28,995 $ 10 70 10.00 20,057,006 $ 5 200 Following is a summary of outstanding stock warrants activity for the three months ended March 31, 2022: Schedule of Outstanding Stock Warrants Number of Exercise Price Weighted Warrants as of December 31, 2021 20,057,156 $ 2 290 $ 5.21 Issued - $ - $ - Expired and forfeited (150 ) $ 200 $ 200 Exercised - $ - $ - Warrants as of March 31, 2022 20,057,006 $ 2 290 $ 5.20

Income Taxes _ Results of Opera

Income Taxes – Results of Operations	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes – Results of Operations	6. Income Taxes – Results of Operations There was no For U.S. federal purposes the corporate statutory income tax rate was 21

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2021 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value .
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of the Company’s investment in the common stock of Statera BioPharma, Inc. (“STAB”) has been measured based on the quoted per share price as reported on NASDAQ and reflects an impairment loss as of March 31, 2022. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of March 31, 2022 and 2021, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2022, and 2021, the Company does not have any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company did not grant any stock-based compensation awards during the three months ended March 31, 2022 and 2021. The Company measures and recognizes compensation expense for share-based awards based on estimated fair values equalling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation-Stock Compensation
Net (Loss) Income per Share	Net (Loss) Income per Share For the three months ended March 31, 2022, basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For the three months ended March 31, 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. The Company’s potential dilutive securities, which include stock warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. For the three-month ended March 31, 2021, basic net income per share was calculated by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted income per share, for the three-month period ended March 31, 2021, was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method and the if-converted method. A reconciliation for the three-month period ended March 31, 2021 of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Diluted Earnings per Share Net Income Weighted Average Per Share Amount Basic EPS Income available to common stockholders $ 790,407 478,305 $ 1.65 Diluted EPS Effect of warrants convertible into common stock - 20,012,083 - Potential shares purchasable using proceeds of warrants - (3,925,915 ) - Effect of convertible debt - 30,422 - Income available to common stockholders $ 790,407 16,594,895 $ 0.05
Recent Accounting Standards	Recent Accounting Standards The Company has reviewed the accounting pronouncements issued by the Financial Accounting Standards Board during the first quarter 2022. Applicable pronouncements will be adopted by the Company in accordance with the accounting guidance and definition. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Basic and Diluted Earnings per Share	A reconciliation for the three-month period ended March 31, 2021 of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Basic and Diluted Earnings per Share Net Income Weighted Average Per Share Amount Basic EPS Income available to common stockholders $ 790,407 478,305 $ 1.65 Diluted EPS Effect of warrants convertible into common stock - 20,012,083 - Potential shares purchasable using proceeds of warrants - (3,925,915 ) - Effect of convertible debt - 30,422 - Income available to common stockholders $ 790,407 16,594,895 $ 0.05

Notes payable (Tables)

Notes payable (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes Payable on March 31, 2022 and December 31, 2021: Schedule of Notes Payable March 31, 2022 December 31, 2021 $ 70,000 $ 70,000 Promissory notes issued between December 2014 and January 2015. Lender earns interest at 10 36 $ 70,000 $ 70,000 Promissory notes issued between May 2015 and June 2016 and matured between February 2017 and November 2018 2 10 $ 149,500 149,500 Promissory notes were issued in 2016. The notes accrue interest at 2 November 2017 and December 2017 $ 606,500 606,500 Promissory notes were issued in 2017 accrue interest at 2 January 2018 and September 2018 $ 205,000 205,000 Promissory notes were issued in 2017 accrue interest at 2 May 2018 $ 150,000 150,000 Promissory notes were issued in 2017 accrue interest at 2 August 2018 and September 2018 $ 116,800 116,800 Promissory notes were issued in 2017 accrue interest at 2 $ 105,500 105,500 Promissory notes were issued in the 2018 accrue interest at 2 May 2018 and January 2019 $ 47,975 47,975 Promissory notes were issued in 2018 accrue interest at 2 July 2018 and October 2018 1,000 5,000 5 $ 65,000 65,000 Promissory notes were issued in 2018. The notes accrue interest at 2 August 2019 and January 2019 60,000 500,000 0.05 $ 118,000 118,000 Promissory notes were issued in 2018. The notes accrue interest at 2 January 2019 and November 2019 200 39,500 5 40 $ 323,855 323,855 Promissory note was issued to a related party in the first quarter of 2019. The note accrues interest at 2 July 2019 4,600 5 $ 23,000 23,000 Promissory note was issued in the first quarter of 2019. The note accrues interest at 6 February 2020 $ 231,478 231,478 Promissory note was issued in the second quarter of 2019 accrues interest at 2 July 2019 10,000 5 $ 10,000 10,000 Promissory note issued in October 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15 1,875 April 30, 2021 $ 150,000 150,000 Promissory note issued in the third quarter of 2020 accrues interest at 12 August 2021 5,402 February 2021 - 53,000 Promissory notes issued in the first quarter of 2021 in connection with a Note Purchase Agreement with a previous note holder. The new notes reflect all principal, interest and penalties associated with the original instrument. These notes accrue interest at 5 7 348,800 March 2022 $ 697,600 697,600 $ 3,070,208 $ 3,070,208

Capital Structure _ Common St_2

Capital Structure – Common Stock and Stock Purchase Warrants (Tables)	3 Months Ended
	Mar. 31, 2022
Capital Structure Common Stock And Stock Purchase Warrants
Schedule of Outstanding Common Stock Warrant	The following is a summary of outstanding common stock warrants for the three-month period ended March 31, 2022. Schedule of Outstanding Common Stock Warrant Expiration Date Number of Shares Exercise Price Remaining Life (years) Second Quarter 2022 1,750 $ 150 .25 Third Quarter 2022 1,650 $ 50 100 .50 Fourth Quarter 2022 9,811 $ 80 290 .75 First Quarter 2023 1,204,000 $ 5 40 1.00 Second Quarter 2023 802,000 $ 5 200 1.25 Third Quarter 2023 7,521,500 $ 5 100 1.50 Fourth Quarter 2023 6,024,300 $ 2 5 1.75 First Quarter 2024 3,660,000 $ 5 2.00 Second Quarter 2024 800,000 $ 5 2.25 Third Quarter 2028 3,000 $ 70 6.50 Second Quarter 2032 28,995 $ 10 70 10.00 20,057,006 $ 5 200
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants activity for the three months ended March 31, 2022: Schedule of Outstanding Stock Warrants Number of Exercise Price Weighted Warrants as of December 31, 2021 20,057,156 $ 2 290 $ 5.21 Issued - $ - $ - Expired and forfeited (150 ) $ 200 $ 200 Exercised - $ - $ - Warrants as of March 31, 2022 20,057,006 $ 2 290 $ 5.20

Company Overview (Details Narra

Company Overview (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 436,888
Working capital	10,867,056
Stockholders' equity	(10,867,056)	$ (10,743,883)	$ (7,948,256)	$ (11,666,981)
Net income loss	2,556,550	(790,407)
Net Income (Loss) Attributable to Parent	(2,556,550)	$ 790,407
Nonoperating gains (losses)	$ 1,178,230

Schedule of Basic and Diluted E

Schedule of Basic and Diluted Earnings per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounting Policies [Abstract]
Basic EPS, Income available to common stockholders		$ 790,407
Basic EPS, Weighted average common shares, basic	483,714	478,305
Basic earnings per share	$ (5.29)	$ 1.65
Diluted EPS, Effect of warrants convertible into common stock
Diluted EPS, Weighted average common shares, diluted		20,012,083
Diluted earnings per share
Diluted EPS, Potential shares purchasable using proceeds of warrants
Diluted EPS, Weighted average common shares, Potential shares		(3,925,915)
Potential shares, Diluted earnings per share
Diluted EPS, Effect of convertible debt
Diluted EPS, Weighted average common shares, Effect of convertible debt		30,422
Effect of convertible debt, Diluted earnings per share
Diluted EPS, Income available to common stockholders		$ 790,407
Diluted EPS, Weighted average common shares, Available to stockholders		16,594,895
Available to stockholders, Diluted earnings per share		$ 0.05

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Mar. 31, 2022USD ($)
Accounting Policies [Abstract]
Cash at federal deposit	$ 250,000

Investment in Common Stock (Det

Investment in Common Stock (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Cleveland BioLabs, Inc. [Member]
Stock issued, shares acquisitions		1,150,000
Stratera BioPharma Inc [Member]
Share price	$ 0.32
Market risk benefit, change in fair value, gain (loss)	$ 2,282,500

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Notes Payable	$ 3,070,208	$ 3,070,208
Notes Payable One [Member]
Short-Term Debt [Line Items]
Notes Payable	70,000	70,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes Payable	149,500	149,500
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Notes Payable	606,500	606,500
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Notes Payable	205,000	205,000
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Notes Payable	150,000	150,000
Notes Payable Six [Member]
Short-Term Debt [Line Items]
Notes Payable	116,800	116,800
Notes Payable Seven [Member]
Short-Term Debt [Line Items]
Notes Payable	105,500	105,500
Notes Payable Eight [Member]
Short-Term Debt [Line Items]
Notes Payable	47,975	47,975
Notes Payable Nine [Member]
Short-Term Debt [Line Items]
Notes Payable	65,000	65,000
Notes Payable Ten [Member]
Short-Term Debt [Line Items]
Notes Payable	118,000	118,000
Notes Payable Eleven [Member]
Short-Term Debt [Line Items]
Notes Payable	323,855	323,855
Notes Payable Twelve [Member]
Short-Term Debt [Line Items]
Notes Payable	23,000	23,000
Notes Payable Thirteen [Member]
Short-Term Debt [Line Items]
Notes Payable	231,478	231,478
Notes Payable Fourteen [Member]
Short-Term Debt [Line Items]
Notes Payable	10,000	10,000
Notes Payable Fifteen [Member]
Short-Term Debt [Line Items]
Notes Payable	150,000	150,000
Notes Payable Sixteen [Member]
Short-Term Debt [Line Items]
Notes Payable		53,000
Notes Payable Seventeen [Member]
Short-Term Debt [Line Items]
Notes Payable	$ 697,600	$ 697,600

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)

Oct. 31, 2019

Feb. 28, 2021

Jan. 31, 2015

Mar. 31, 2021

Sep. 30, 2020

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Jun. 30, 2016

Mar. 31, 2022

Short-Term Debt [Line Items]

Class of warrant or right, outstanding

20,057,006

Minimum [Member]

Short-Term Debt [Line Items]

Class of warrant or right, exercise price

$ 5

Maximum [Member]

Short-Term Debt [Line Items]

Class of warrant or right, exercise price

$ 200

Notes Payable One [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

10.00%

Number of installments

36 months

Notes Payable Two [Member]

Short-Term Debt [Line Items]

Debt instrument maturity date description

February 2017 and November 2018

Notes Payable Two [Member] | Minimum [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Notes Payable Two [Member] | Maximum [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

10.00%

Notes Payable Three [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

November 2017 and December 2017

Notes Payable Four [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

January 2018 and September 2018

Notes Payable Five [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

May 2018

Notes Payable Six [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

August 2018 and September 2018

Notes Payable Seven [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Notes Payable Eight [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

May 2018 and January 2019

Notes Payable Nine [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July 2018 and October 2018

Class of warrant or right, exercise price

$ 5

Notes Payable Nine [Member] | Minimum [Member]

Short-Term Debt [Line Items]

Class of warrant or right, outstanding

1,000

Notes Payable Nine [Member] | Maximum [Member]

Short-Term Debt [Line Items]

Class of warrant or right, outstanding

5,000

Notes Payable Ten [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

August 2019 and January 2019

Class of warrant or right, exercise price

$ 0.05

Notes Payable Ten [Member] | Minimum [Member]

Short-Term Debt [Line Items]

Class of warrant or right, outstanding

60,000

Notes Payable Ten [Member] | Maximum [Member]

Short-Term Debt [Line Items]

Class of warrant or right, outstanding

500,000

Notes Payable Eleven [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

January 2019 and November 2019

Notes Payable Eleven [Member] | Minimum [Member]

Short-Term Debt [Line Items]

Class of warrant or right, outstanding

200

Class of warrant or right, exercise price

$ 5

Notes Payable Eleven [Member] | Maximum [Member]

Short-Term Debt [Line Items]

Class of warrant or right, outstanding

39,500

Class of warrant or right, exercise price

$ 40

Notes Payable Twelve [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July 2019

Class of warrant or right, outstanding

4,600

Class of warrant or right, exercise price

$ 5

Notes Payable Thirteen [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

6.00%

Debt instrument maturity date description

February 2020

Notes Payable Fourteen [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July 2019

Class of warrant or right, outstanding

10,000

Class of warrant or right, exercise price

$ 5

Notes Payable Fifteen [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

15.00%

Debt instrument maturity date description

April 30, 2021

Debt instrument, periodic payment

$ 1,875

Notes Payable Sixteen [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

12.00%

Debt instrument maturity date description

August 2021

Debt converted shares

5,402

Notes Payable Seventeen [Member]

Short-Term Debt [Line Items]

Percentage of interest rate per annum

5.00%

Debt instrument maturity date description

March 2022

Debt penalty percentage

7.00%

Debt Instrument, Face Amount

$ 348,800

Notes payable (Details Narrativ

Notes payable (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Accrued interest	$ 656,484	$ 564,300
Notes payable to shareholders	$ 1,677,275	$ 1,677,275

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrant (Details)	Mar. 31, 2022$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Shares | shares	20,057,006
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 200
Second Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,750
Exercise Price	$ 150
Remaining Life (years)	3 months
Third Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,650
Remaining Life (years)	6 months
Third Quarter 2022 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 50
Third Quarter 2022 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 100
Fourth Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	9,811
Remaining Life (years)	9 months
Fourth Quarter 2022 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 80
Fourth Quarter 2022 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 290
First Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,204,000
Remaining Life (years)	1 year
First Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
First Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 40
Second Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	802,000
Remaining Life (years)	1 year 3 months
Second Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Second Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 200
Third Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	7,521,500
Remaining Life (years)	1 year 6 months
Third Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Third Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 100
Fourth Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	6,024,300
Remaining Life (years)	1 year 9 months
Fourth Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2
Fourth Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
First Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	3,660,000
Exercise Price	$ 5
Remaining Life (years)	2 years
Second Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	800,000
Exercise Price	$ 5
Remaining Life (years)	2 years 3 months
Second Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	3,000
Exercise Price	$ 70
Remaining Life (years)	6 years 6 months
Second Quarter 2032 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	28,995
Remaining Life (years)	10 years
Second Quarter 2032 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 10
Second Quarter 2032 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 70

Schedule of Outstanding Stock W

Schedule of Outstanding Stock Warrants (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Number of Shares Warrants, Beginning balance | shares	20,057,156
Weighted Average Price, Beginning balance	$ 5.21
Number of Shares Warrants, Issued | shares
Exercise Price, Issued
Weighted Average Price, Issued
Number of Shares Warrants, Expired and forfeited | shares	(150)
Exercise Price, Expired and forfeited	$ 200
Weighted Average Price, Expired and forfeited	$ 200
Number of Shares Warrants, Exercised | shares
Exercise Price, Exercised
Weighted Average Price, Exercised
Number of Shares Warrants, Ending balance | shares	20,057,006
Weighted Average Price, Ending balance	$ 5.20
Minimum [Member]
Exercise Price	2
Exercise Price	2
Maximum [Member]
Exercise Price	290
Exercise Price	$ 290

Capital Structure _ Common St_3

Capital Structure – Common Stock and Stock Purchase Warrants (Details Narrative)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Class of Warrant or Right, Outstanding	20,057,006
Thirty-One Warrant Holders [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Class of Warrant or Right, Outstanding	18,730,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5
Stockholders' Equity, Reverse Stock Split	warrant shares and the exercise price per share at 10-to-1

Income Taxes _ Results of Ope_2

Income Taxes – Results of Operations (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0
Statutory income tax rate	21.00%	21.00%